arrow
J

Jens Panse

RWTH Aachen University
H指数:43
被引数:9,754

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients

抗真菌预防时代慢性播散性念珠菌病的治疗与预后:一项包含111例患者的回顾性多中心队列研究

2026-09-010
OAAI
Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial

艾曲波帕联合环孢素A治疗中度再生障碍性贫血(EMAA):一项安慰剂对照、双盲、III期临床试验

Blood
IF23.1
2026-08-200
OAAI
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial

高强度化疗后行自体干细胞移植与低强度巩固治疗在原发性中枢神经系统淋巴瘤中的比较(MATRix/IELSG43):一项随机三期临床试验

2026-07-220
PRE
Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study

缩短血液和肿瘤疾病男性患者中心静脉导管留置时间以预防中心静脉导管相关血流感染:一项目标试验模拟研究

2026-07-100
OAAI
CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis

靶向CD117的CAR T细胞在先进系统性肥大细胞增多症的临床前模型中有效清除肥大细胞

Leukemia
IF13.4
2026-05-070
OAAI
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study

阿伐普利尼布在晚期系统性肥大细胞增多症中的有效性和安全性:PATHFINDER研究的4年随访

2026-01-300
OAAI
CNS infections in patients with hematological or oncological diseases (including cellular therapies) – 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

血液病或肿瘤性疾病患者(包括细胞疗法)的CNS感染——德国血液学与肿瘤学学会(DGHO)感染性疾病工作组(AGIHO)指南的2024年更新版

2025-11-100
PRE
Allogeneic stem cell transplantation from variant-carrying family donors leads to long-term engraftment in Telomere Biology Disorders

携带变异的家系供者异基因干细胞移植可导致端粒生物学疾病患者的长期植入

2025-08-250
OAAI
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors

口服iptacopan单药治疗阵发性夜间血红蛋白尿症:来自在抗C5治疗患者中进行的开放标签、随机、III期APPLY-PNH试验和既往未经补体抑制剂治疗的患者的开放标签、单臂、III期APPOINT-PNH试验的最终48周结果

2025-05-280
PRE
PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma

PFS24作为新诊断原发性中枢神经系统淋巴瘤患者的预后里程碑

2025-04-240
OA
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
2025-01-210
OA
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

达尼可潘作为拉武利珠单抗或依库珠单抗的附加疗法在阵发性夜间血红蛋白尿症患者中的长期患者报告结局:来自3期ALPHA试验的数据

BLOOD
IF23.1
2024-11-050
PRE
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

III期随机COMMODORE 1试验:从艾库努单抗转换治疗的阵发性夜间血红蛋白尿(PNH)患者中克罗瓦利单抗的2年安全性与有效性

BLOOD
IF23.1
2024-11-050
PRE
Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naive Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

欧洲和加拿大接受Pegcetacoplan治疗的补体抑制剂经治和补体抑制剂初治的阵发性夜间血红蛋白尿患者的真实世界临床结局

BLOOD
IF23.1
2024-11-050
PRE